搜索结果111-120 的 860 / anti-TNF drugs

  1. 乳腺专科门诊- 临床试验- 妙佑医疗国际

    ... therapy medicines. Study of Breast Cancer Risk Assessment in Female Patients with Benign Breast Disease. Rochester, Minn., Jacksonville, Fla. The purpose of ...

  2. 神经科- 临床试验- 妙佑医疗国际

    Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma ... drugs in the iPSC-derived muscle cells ...

  3. 神经科- 临床试验- 妙佑医疗国际

    ... therapy and allow for collaborative research. The PPCR will collect ... drugs in the iPSC-derived muscle cells. Cerebral Spinal Fluid Evaluation in ...

  4. 住院内科- 临床试验- 妙佑医疗国际

    ... therapy is in achieving euvolemia and the impact of their quantitated volume status at the time of hospital discharge on heart failure related morality and ...

  5. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  6. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  7. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  8. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  9. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...

  10. 神经科- 临床试验- 妙佑医疗国际

    Patients in cohorts 1.11 and 1.12 (currently lacking detectable cancer) will undergo the collection at least 4 weeks after conclusion of therapy. In addition to ...